1
|
Munteanu C, Schwartz B. The Effect of Bioactive Aliment Compounds and Micronutrients on Non-Alcoholic Fatty Liver Disease. Antioxidants (Basel) 2023; 12:antiox12040903. [PMID: 37107278 PMCID: PMC10136128 DOI: 10.3390/antiox12040903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2023] [Revised: 03/28/2023] [Accepted: 04/08/2023] [Indexed: 04/29/2023] Open
Abstract
In the current review, we focused on identifying aliment compounds and micronutrients, as well as addressed promising bioactive nutrients that may interfere with NAFLD advance and ultimately affect this disease progress. In this regard, we targeted: 1. Potential bioactive nutrients that may interfere with NAFLD, specifically dark chocolate, cocoa butter, and peanut butter which may be involved in decreasing cholesterol concentrations. 2. The role of sweeteners used in coffee and other frequent beverages; in this sense, stevia has proven to be adequate for improving carbohydrate metabolism, liver steatosis, and liver fibrosis. 3. Additional compounds were shown to exert a beneficial action on NAFLD, namely glutathione, soy lecithin, silymarin, Aquamin, and cannabinoids which were shown to lower the serum concentration of triglycerides. 4. The effects of micronutrients, especially vitamins, on NAFLD. Even if most studies demonstrate the beneficial role of vitamins in this pathology, there are exceptions. 5. We provide information regarding the modulation of the activity of some enzymes related to NAFLD and their effect on this disease. We conclude that NAFLD can be prevented or improved by different factors through their involvement in the signaling, genetic, and biochemical pathways that underlie NAFLD. Therefore, exposing this vast knowledge to the public is particularly important.
Collapse
Affiliation(s)
- Camelia Munteanu
- Department of Plant Culture, Faculty of Agriculture, University of Agricultural Sciences and Veterinary Medicine, 400372 Cluj-Napoca, Romania
| | - Betty Schwartz
- The Institute of Biochemistry, Food Science and Nutrition, The School of Nutritional Sciences, Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, Rehovot 76100, Israel
| |
Collapse
|
2
|
Plaz Torres MC, Aghemo A, Lleo A, Bodini G, Furnari M, Marabotto E, Miele L, Giannini EG. Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered. Nutrients 2019; 11:2971. [PMID: 31817398 PMCID: PMC6949938 DOI: 10.3390/nu11122971] [Citation(s) in RCA: 56] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2019] [Revised: 11/28/2019] [Accepted: 11/30/2019] [Indexed: 12/16/2022] Open
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and is expected to become the leading cause of end-stage liver disease worldwide over the next few decades. In fact, NAFLD encompasses different clinical scenarios, from the simple accumulation of fat (steatosis) to steatohepatitis (NASH), NASH-cirrhosis, and cirrhosis complications. In this context, it is fundamental to pursue strategies aimed at both preventing the disease and reducing the progression of liver fibrosis once liver damage is already initiated. As of today, no pharmacological treatment has been approved for NAFLD/NASH, and the only recommended treatment of proven efficacy are life-style modifications, including diet and physical exercise pointing at weight loss of 5%-7%. Different dietetic approaches have been proposed in this setting, and in this review, we will discuss the evidence regarding the efficacy of the Mediterranean Diet as a treatment for NAFLD. In particular, we will report the effects on liver-related outcomes.
Collapse
Affiliation(s)
- Maria Corina Plaz Torres
- Cattedra di Gastroenterologia, Dipartimento di Medicina Interna, Università degli Studi di Genova, 16132 Genova, Italy
- Programma Dipartimentale Diagnosi e Terapia delle Malattie Emergenti dell’Apparato Digerente, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy
- Divisione di Medicine Interna ed Epatologia, Humanitas Clinical and Research Center-IRCCS, 20089 Rozzano, Italy
| | - Alessio Aghemo
- Divisione di Medicine Interna ed Epatologia, Humanitas Clinical and Research Center-IRCCS, 20089 Rozzano, Italy
- Dipartimento di Scienze Biomediche, Humanitas University, 20090 Pieve Emanuele, Italy
| | - Ana Lleo
- Divisione di Medicine Interna ed Epatologia, Humanitas Clinical and Research Center-IRCCS, 20089 Rozzano, Italy
- Dipartimento di Scienze Biomediche, Humanitas University, 20090 Pieve Emanuele, Italy
| | - Giorgia Bodini
- Cattedra di Gastroenterologia, Dipartimento di Medicina Interna, Università degli Studi di Genova, 16132 Genova, Italy
- Programma Dipartimentale Diagnosi e Terapia delle Malattie Emergenti dell’Apparato Digerente, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy
- Divisione di Medicine Interna ed Epatologia, Humanitas Clinical and Research Center-IRCCS, 20089 Rozzano, Italy
| | - Manuele Furnari
- Cattedra di Gastroenterologia, Dipartimento di Medicina Interna, Università degli Studi di Genova, 16132 Genova, Italy
| | - Elisa Marabotto
- Cattedra di Gastroenterologia, Dipartimento di Medicina Interna, Università degli Studi di Genova, 16132 Genova, Italy
| | - Luca Miele
- Area Medicina Interna, Gastroenterologia e Medicina Interna, Fondazione Policlinico Gemelli IRCCS, Università Cattolica del Sacro Cuore, 20123 Roma, Italy
| | - Edoardo G. Giannini
- Cattedra di Gastroenterologia, Dipartimento di Medicina Interna, Università degli Studi di Genova, 16132 Genova, Italy
- Programma Dipartimentale Diagnosi e Terapia delle Malattie Emergenti dell’Apparato Digerente, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy
- Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Viale Benedetto XV, no.6, 16132 Genoa, Italy
| |
Collapse
|
3
|
Effect of Mediterranean Diet and Antioxidant Formulation in Non-Alcoholic Fatty Liver Disease: A Randomized Study. Nutrients 2017; 9:nu9080870. [PMID: 28805669 PMCID: PMC5579663 DOI: 10.3390/nu9080870] [Citation(s) in RCA: 95] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2017] [Revised: 07/20/2017] [Accepted: 08/08/2017] [Indexed: 12/12/2022] Open
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide, characterized by liver fatty acid accumulation and fibrosis, not due to excessive alcohol consumption. Notably, nutritional habits have been reported to be implicated in the onset and severity of the hepatic damage, while the Mediterranean diet has shown beneficial effects on NAFLD. Free radicals and oxidative stress were suggested to be involved in the pathogenesis and progression of NAFLD, and several data highlighted the efficacy of antioxidant supplementation in its treatment. The aim of this study was to compare the effects of the Mediterranean diet, with or without an antioxidant complex supplement, in overweight patients suffering from NAFLD. In this prospective study, fifty Caucasian overweight patients were randomized into three groups (Groups A-C). A personalized moderately hypocaloric Mediterranean diet was prescribed to all patients included in the A and B groups. In addition to the diet, Group B was administered antioxidant supplementation daily and for the period of six months. Group C did not have any type of treatment. The study proved that the Mediterranean diet alone or in association with the antioxidant complex improved anthropometric parameters, lipid profile and reduced hepatic fat accumulation and liver stiffness. However, Group B patients, in which the diet was associated with antioxidant intake, showed not only a significant improvement in insulin sensitivity, but also a more consistent reduction of anthropometric parameters when compared with Group A patients. Taken together, these results support the benefit of antioxidant supplementation in overweight patients with NAFLD.
Collapse
|